1st Faculty of Medicine Charles University 1st Faculty of Medicine Charles University Hematology laboratories
lvysa 13.02.2024

Poslechněte si videokomentáře z letošní konference HEMATOLOGIE 2024

Co se událo na poli české a světové hematologie? ZDE  294

lvysa 08.01.2024

Cena kolegia děkana 1.LF UK za excelentní publikaci 2022

Stopka T, Minařík L, Dusilková N, Pešta M, Kulvait V, Špaček M, Zemanová Z, Kalousová M, Jonášová A. G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial. Blood Cancer J. 2022 Jul 7;12(7):105. doi: 10.1038/s41408-022-00698-2. (PubMed)

Pimkova K, Jassinskaja M, Munita R, Ciesla M, Guzzi N, Cao Thi Ngoc P, Vajrychova M, Johansson E, Bellodi C, Hansson J. Quantitative analysis of redox proteome reveals oxidation-sensitive protein thiols acting in fundamental processes of developmental hematopoiesis. Redox Biol. 2022 Jul;53:102343. doi: 10.1016/j.redox.2022.102343. (PubMed)

290  291

lvysa 21.06.2023

EHA 2023 Frankfurt

Comments from EHA2023 in Frankfurt - prof. Stopka and Dr. Pimková (in Czech).   285

288  289

lvysa 29.03.2023

Czech physicians and researchers to prolong the lives of people with leukaemia

A team of researchers and physicians from the BIOCEV Centre, 1st Department of Medicine - Hematology (the First Faculty of Medicine of Charles University) and the General University Hospital in Prague has designed a new approach for the treatment of acute leukaemia. This innovative method involves the combination of two medicines that, when administered together, have significantly prolonged the survival of patients. The clinical trial lasted five years and included 76 patients from the Czech Republic. Information about the new type of treatment was published by the prestigious Blood Cancer Journal from the Nature Publishing Group. At the moment, negotiations are underway to expand the trial to the European-wide level.

Doc. Anna Jonášová and Prof. Tomáš Stopka  

238 234 



235












Myelodysplastic syndrome (MDS) is a cancer of the bone marrow causing a low production of non-functioning blood cells. As a result, patients are deficient in both red and white blood cells, which are crucial for the body’s immunity, as well as platelets for blood coagulation. Patients suffering from this anaemia suffer from bruising, frequent internal bleeding and are less resistant to bacterial and viral infections, for example pneumonia.

Depending on the severity of the disease, antibiotics or repeated blood transfusions are given as treatment. In exceptional cases, patients can be treated with a bone marrow transplant. In Europe, four MDS patients per 100,000 people are diagnosed annually. In the Czech Republic, the General University Hospital registers approximately 80 patients each year. The critical phase of MDS is the transition to acute myeloid leukaemia (AML), characterised with a very short survival time.

"The current globally applied treatment for MDS patients during their transition to AML is based on 5-azacytidine, a medicine which was invented in the 1970s by the Czechoslovak Academy of Sciences. Azacytidine is an inhibitor of nuclear enzymes, referred to as DNA methylases, which are genetically and functionally disrupted in leukemic cells, and therefore, their activity helps to eliminate leukemic cells. Based on previous research, much of which has been published in reputable journals, our MDS/AML group has come up with the concept of “differentiation therapy for MDS”. We propose combining azacytidine with another substance called G-CSF, which promotes the formation and development of white blood cells in the bone marrow. We have been able to demonstrate the therapeutic effects of the new combination, and, above all, its safe effect on patients, but we have also been able to prolong their survival by months,” says Prof. Tomáš Stopka, head of research from the First Faculty of Medicine, Charles University, and Biocev. “At the same time, we have discovered that the combination of these agents induced significantly more treatment responses, which is ground-breaking and essential for further research and clinical testing in patients.”

A clinical trial demonstrating the benefit of the new treatment method in high-risk MDS was approved by the State Institute for Drug Control in 2017. The coordinator of the clinical trial was the Head of MDS and AML Treatment and Diagnosis, Doc. Anna Jonášová from the 1st Internal Clinic – Haematology, First Faculty of Medicine, Charles University in Prague: “We had to make a huge effort even before the trial itself was launched as we had to secure an application with the State Institute for Drug Control and have the trial pass through the ethics committees. The proposed therapeutic combination advances the use of the cytokine G-CSF in AML therapy, while its synergistic activity with azacytidine makes this treatment more effective and safer for patients, representing a proven strategy that is immediately applicable in practice. We would not have achieved the results if it had not been for the great willingness of the patients who participated in the trial."

At the moment, intensive negotiations are underway for a new European-wide trial in which another medicine, Venetoclax, will be investigated alongside 5-azacytidine and G-CSF. "I am happy that we are successfully linking genetic and clinical data in the Czech Republic and thanks to this, we are able to determine how acute leukaemia will be treated in the near future," adds Prof. Tomáš Stopka.

Link to the publication: HERE

Rozhovor pro UK FORUM: Nová kombinace léčiv prodlužuje život pacientů s leukémií (ukforum.cz)

lvysa 17.04.2023

Medical Tribune - Ročník XIX, číslo 6

 Article about our research in Medical Tribune (in czech)         

lvysa 29.03.2023

Tomáš Stopka: G-CSF plus azacitidine versus azacitidine alone

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.Stopka T, Minařík L, Dusilková N, Pešta M, Kulvait V, Špaček M, Zemanová Z, Kalousová M, Jonášová A. Blood Cancer J. 2022 Jul 7;12(7):105. doi: 10.1038/s41408-022-00698-2. (IF 11.98) [link]

  230  231  232 224




233





Rozhovor pro UK FORUM: Nová kombinace léčiv prodlužuje život pacientů s leukémií (ukforum.cz)

TZ BIOCEV: Čeští lékaři a vědci prodlouží život lidem s leukémií | Biocev

lvysa 29.03.2023

Kristýna Pimková: Quantitative analysis of redox proteome

Quantitative analysis of redox proteome reveals oxidation-sensitive protein thiols acting in fundamental processes of developmental hematopoiesis. Pimkova K, Jassinskaja M, Munita R, Ciesla M, Guzzi N, Cao Thi Ngoc P, Vajrychova M, Johansson E, Bellodi C, Hansson J. Redox Biology. Volume 53, July 2022, 102343. ISSN 2213-2317. https://doi.org/10.1016/j.redox.2022.102343. (IF 11.79) [PubMed]

277  278
 



 

lvysa 28.03.2023

Tomáš Stopka: Circulating microRNAs in Cerebrospinal Fluid and Plasma

Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas. Krsmanovic P, Mocikova H, Chramostova K, Klanova M, Trnkova M, Pesta M, Laslo P, Pytlik R, Stopka T, Trneny M, Pospisil V. Cancers. 2022; 14(9):2305. https://doi.org/10.3390/cancers14092305 (IF 6.6) [link]

218  220

lvysa 29.03.2023

Petra Bašová: Combined Approach to Leukemic Differentiation

Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents. Bašová P, Paszeková H, Minařík L, Dluhošová M, Burda P, Stopka T. Int J Mol Sci. 2022 Jun 16;23(12):6729. doi: 10.3390/ijms23126729. (IF 5.9) [PubMed]

240  241

lvysa 29.03.2023

Shefali Thakur: Chromatin remodeler Smarca5

Chromatin Remodeler Smarca5 Is Required for Cancer-Related Processes of Primary Cell Fitness and Immortalization. Thakur S, Cahais V, Turkova T, Zikmund T, Renard C, Stopka T, Korenjak M, Zavadil J. Cells 2022, 11,808. https://doi.org/10.3390/cells11050808 (IF 6.6) [PDF

209

217

lvysa 29.03.2023

Kristýna Pimková: Peroxiredoxin 6

Peroxiredoxin 6 protects irradiated cells from oxidative stress and shapes their senescence-associated cytokine landscape. Salovska B, Kondelova A, Pimkova K, Liblova Z, Pribyl M, Fabrik I, Bartek J, Vajrychova M, Hodny Z. Redox Biol. 2022 Feb;49:102212. doi: 10.1016/j.redox.2021.102212. (IF 10.79) [PubMed]

 

281  282
 



 

lvysa 29.03.2023

Ľubomír Minařík: Analysis of 5-Azacytidine Resistance

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways. Minařík L, Pimková K, Kokavec J, Schaffartziková A, Vellieux F, Kulvait V, Daumová L, Dusilková N, Jonášová A, Vargová KS, Králová Viziová P, Sedláček R, Zemanová Z, Stopka T. Cells. 2022; 11(2):223. https://doi.org/10.3390/cells11020223. (IF 6.6) [PDF]    209

207

lvysa 29.03.2023

Pavel Čabart: Universal Promoter Scanning

Universal promoter scanning by Pol II during transcription initiation in Saccharomyces cerevisiae. Qiu C, Jin H, Vvedenskaya I, Llenas JA, Zhao T, Malik I, Visbisky AM, Schwartz SL, Cui P, Čabart P, Han KH, Lai W, Metz RP, Johnson CD, Sze SH, Pugh BF, Nickels BE & Kaplan, CD (2020). Genome biology, 21(1), 132. https://doi.org/10.1186/s13059-020-02040-0. (IF 14.028) [PubMed] (131)

197 198
lvysa 29.03.2023

Tomáš Zikmund - Helena Paszeková: Loss of ISWI ATPase SMARCA5 (SNF2H)

Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits Proliferation and Chromatid Cohesion. Zikmund T, Paszekova H, Kokavec J, Kerbs P, Thakur S, Turkova T, Tauchmanova P, Greif PA, Stopka T. Int J Mol Sci. 2020;21(6):E2073. Published 2020 Mar 18.doi:10.3390/ijms21062073. (IF 4.183) [PubMed]


195 76 196

 

lvysa 29.03.2023

Tomáš Stopka: Aberrantly elevated suprabasin

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes. Pribyl M, Hubackova S, Moudra A, Vancurova M, Polackova H, Stopka T, Jonasova A, Bokorova R, Fuchs O, Stritesky J, Salovska B, Bartek J, Hodny Z. [published online ahead of print, 2020 Jul 21]. Mol Oncol. 2020;10.1002/1878-0261.12768. doi:10.1002/1878-0261.12768. (IF 6.574) [PubMed] 202

201

lvysa 29.03.2023

Tomáš Stopka: Chromatin remodeler Snf2h

The chromatin remodeler Snf2h is essential for oocyte meiotic cell cycle progression. Zhang C, Chen Z, Yin Q, Fu X, Li Y, Stopka T, Skoultchi AI, Zhang Y. Genes Dev. 2020 Jan 9. doi: 10.1101/gad.331157.119. (IF 8.998) [Pubmed


189 191

 

lvysa 29.03.2023

Ľubomír Minařík: Azacitidine Switch to Lenalidomide

Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS. Minarik L, Zemanova Z, Kulvait V, Dluhosova M, Jonasova A and Stopka T. Ann Hematol Oncol. 2019; 6(1): 0000. [PDF] (IF 2.219

180 181
lvysa 29.03.2023

Tomáš Stopka: MDS News

Randomizovaná otevřená akademická studie: srovnání standardního podání azacytidinu oproti azacytidinu s preinkubací G-CSF u myelodysplastického syndromu vyššího rizika – interim analýza. Stopka T, Minařík Ĺ, Kulvait V, Pešta M, Schaffartziková A, Kislik G, Dusílková N, Zemanová Z, Jonášová A. Myelodysplastic Syndrome News. Listopad 2019. Ročník 7 / číslo 2. [PDF]


188

 

lvysa 29.03.2023

Tomáš Zikmund: ISWI ATPase Smarca5

ISWI ATPase Smarca5 Regulates Differentiation of Thymocytes Undergoing b-selection. Zikmund T, Kokavec J, Turkova T, Savvulidi F, Paszekova H, Vodenkova S, Sedlacek R, Skoultchi AI, Stopka T.. J Immunol. 2019 Jun 15;202(12):3434-3446. doi: 10.4049/jimmunol.1801684. Epub 2019 May 8. [PubMed] (IF 4.539) 185

186
lvysa 29.03.2023

Reputable publication in Haematologica July 2018

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Machova Polakova K. Haematologica. 2018 Jul 26. pii: haematol.2018.193086. doi: 10.3324/haematol.2018.193086. [PubMed] (IF 9.09)

178
lvysa 29.03.2023

Anna Jonášová: Lenalidomide treatment in lower risk myelodysplastic syndromes

Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin±prednisone addition to lenalidomide in refractory or relapsed patients). Jonasova A, Neuwirtova R, Polackova H, Siskova M, Stopka T, Cmunt E, Belickova M, Moudra A, Minarik L, Fuchs O, Michalova K, Zemanova Z. Leukemia Research 69 (2018) 12-17. 2018 March 27. https://doi.org/10.1016/j.leukres.2018.03.015 . (IF 2.501) [PDF]

175 174
lvysa 29.03.2023

Kamila Polgárová: Somatic mutation dynamics in MDS patients

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders. Polgarova K, Vargova K, Kulvait V, Dusilkova N, Minarik L, Zemanova Z, Pesta M, Jonasova A and Stopka T. Oncotarget. 2017 Dec 6. (IF 5.168) [PDF] (B, N, H, 131)

  173 172

lvysa 29.03.2023

Nina Dusílková & Petra Bašová: Plasma microRNAs in Cutaneous Lymphoma, in press IJMS

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-cell Lymphomas. Dusilkova N, Basova P, Polivka J, Kodet O, Kulvait V, Pesta M, Trneny M, Stopka T. Int J Mol Sci. 2017 Oct 15;18(10). pii: E2136. doi: 10.3390/ijms18102136. [PDF] (IF: 3.226)

  126 123 125

lvysa 29.03.2023

Petra Bašová: Serum microRNAs in Breast Cancer Relapse prediction, in press in IJMS

Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer. Basova P, Pesta M, Sochor M, Stopka T. Int J Mol Sci. 2017 Oct 10;18(10). pii: E2116. doi: 10.3390/ijms18102116[PDF] (IF: 3.226) 121

122 

lvysa 29.03.2023

Juraj Kokavec: mouse model of Smarca5 in HSCs

Kokavec J, Zikmund T, Savvulidi F, Kulvait V, Edelmann W, Skoultchi AI, Stopka T. The ISWI ATPase Smarca5 (Snf2h) Is Required for Proliferation and Differentiation of Hematopoietic Stem and Progenitor Cells. Stem Cells. 2017 Jun;35(6):1614-1623. doi: 10.1002/stem.2604. [https] (IF: 5.599)

129

lvysa 29.03.2023

Hana Hušková - MS on cancer driver NOW in Oncogene

Huskova H, Ardin M, Weninger A, Vargova K, Barrin S, Villar S, Olivier M, Stopka T, Herceg Z, Hollstein M, Zavadil J, Korenjak M. Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.215. [PDF] (IF: 7.519)
  Výsledek obrázku pro Oncogene logo

 


 

 

 

lvysa 29.03.2023

Karina Vargová - MS on miR-155/miR-150 network in CLL now in press in BCJ

Vargova K, Pesta M, Obrtlíkova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M and Stopka T. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J. 2017 Jul 21;7(7):e585. doi: 10.1038/bcj.2017.63. [PDF] (IF: 6.126)

 

 

 

lvysa 29.03.2023

Jarmila Vargová: MARCKS: new therapeutic target in MCL

Vargova J, Vargova K, Dusilkova N, Kulvait V, Pospisil V, Zavadil J, Trneny M, Klener P, Stopka T. Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia. Blood Cancer J. 2016 Sep 23;6(9):e475. doi: 10.1038/bcj.2016.80. [PDF] (IF: 4.502)

Výsledek obrázku pro Blood Cancer Journal logo




ohlasy v tisku:

http://www.ctidoma.cz/zpravodajstvi-zdravi/2016-10-05-cesti-odbornici-zjistili-jak-vylecit-rakovinu-krve-26743

http://sciencemag.cz/cesti-vedci-na-stope-novym-lekum-proti-lymfomum/

lvysa 29.03.2023

Pavel Burda: addition to BBA, collaborative project with John Strouboulis

Papageorgiou DN, Karkoulia E, Amaral-Psarris A, Burda P, Kolodziej K, Demmers J, Bungert J, Stopka T, Strouboulis J. Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: Evidence for co-repressor functions. Biochim Biophys Acta. 2016 Dec;1859(12):1515-1526. doi: 10.1016/j.bbagrm.2016.09.007. [https] (IF: 5.373) 132